Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.57 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135088 | 0.82 | KDM4E (0.60) | L3MBTL1GLO1SLC40A1LMNATSHR | |
| SCHEMBL8164647 | 0.82 | GLO1 (0.55) | L3MBTL1GLO1SLC40A1METAP2ALDH1A1 | |
| SCHEMBL15314376 | 0.81 | TSHR (0.62) | L3MBTL1GLO1SLC40A1LMNATSHR | |
| SCHEMBL17489126 | 0.81 | L3MBTL1 (0.59) | L3MBTL1GLO1SLC40A1METAP2KAT6A | |
| SCHEMBL22313300 | 0.79 | L3MBTL1 (0.58) | L3MBTL1GLO1SLC40A1METAP2KAT6A | |
| SCHEMBL10734794 | 0.78 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1METAP2KAT6A | |
| SCHEMBL4518372 | 0.78 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1METAP2KAT6A | |
| SCHEMBL2371864 | 0.78 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1METAP2KAT6A | |
| SCHEMBL332569 | 0.78 | TSHR (0.70) | L3MBTL1GLO1SLC40A1AURKADHFR | |
| SCHEMBL29706147 | 0.78 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | SPEEDEL PHARMA AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | SPEEDEL PHARMA AG (CH) | 2010-06-24 | — | — | US | disclosed |
| CN-100453081-C | Pyridylsulfonamido pyrimidines for the treatment of diabetic nephropathy | SPEEDEL PHARMA AG (CH) | 2009-01-21 | — | — | CN | disclosed |
| US-20090005404-A1 | Pyridylsulfonamido pyrimidines for treating diabetic nephropathy | MANN JESSICA | 2009-01-01 | — | — | US | disclosed |
| US-20090005404-A1 | Pyridylsulfonamido pyrimidines for treating diabetic nephropathy | MANN JESSICA | 2009-01-01 | — | — | US | disclosed |
| CN-101257947-A | Pyridylsulfonamidyl-pyrimidines for the prevention of blood vessel graft failure | SPEEDEL PHARMA AG (CH) | 2008-09-03 | — | — | CN | disclosed |
| EP-1924325-A2 | PYRIDYLSULFONAMIDYL-PYRIMIDINES FOR THE PREVENTION OF BLOOD VESSEL GRAFT FAILURE | Speedel Pharma AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1601361-B1 | PYRIDYLSULFONAMIDO PYRIMIDINES FOR TREATING DIABETIC NEPHROPATHY | SPEEDEL PHARMA AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007031501-A2 | PYRIDYLSULFONAMIDYL-PYRIMIDINES FOR THE PREVENTION OF BLOOD VESSEL GRAFT FAILURE | SPEEDEL PHARMA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20060094731-A1 | New medicament | SPEEDEL PHARMA AG (CH) | 2006-05-04 | — | — | US | disclosed |
| CN-1756552-A | Pyridylsulfonamido pyrimidines for the treatment of diabetic nephropathy | SPEEDEL PHARMA AG (CH) | 2006-04-05 | — | — | CN | disclosed |
| EP-1454625-A1 | Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies | Speedel Development AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| EP-1454625-A1 | Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies | Speedel Development AG (CH) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094731-A1 | New medicament | REN, SLC5A1, GLS | L3MBTL1 2027/4885GLO1 236/4885SLC40A1 288/4885 |
| US-20090005404-A1 | Pyridylsulfonamido pyrimidines for treating diabetic nephropathy | PDXK, REN, C5 | L3MBTL1 2376/4885GLO1 834/4885SLC40A1 904/4885 |
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | PDXK, CBS, C1S | L3MBTL1 642/4885GLO1 277/4885SLC40A1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.